A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer (EmpowHER 208)

Jazz Pharmaceuticals

Status and phase: Not yet enrolling; Phase 2

Conditions: Breast Cancer; HER2-positive Breast Cancer

Treatments: Drug: Zanidatamab; Drug: Carboplatin; Drug: Docetaxel; Drug: Paclitaxel; Drug: Pertuzumab; Drug: Trastuzumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT07102381

2025-523204-68-00 (EU Trial (CTIS) Number)

JZP598-208

Details and patient eligibility

About

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Enrollment: 125 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Has Stage II or III histologically confirmed invasive breast carcinoma.
2. Has histologically confirmed HER2-positive breast cancer
3. Has a known hormone receptor (HR) status of the primary tumor
4. Participants with multifocal or multicentric disease are eligible if the largest tumor (which must be larger than or equal to 2 cm in diameter) is HER2-positive, and the treating physician has determined the participant should be treated as HER2-positive.
5. Agrees to undergo a mastectomy or breast conserving surgery (BCS) after neoadjuvant therapy.
6. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. Adequate organ function
8. Has an LVEF ≥ 50% as determined by either ECHO or MUGA obtained within 4 weeks prior to first dose of study intervention.
9. Adequate contraceptive precautions

Exclusion criteria

1. Has Stage IV (metastatic) breast cancer.
2. Has bilateral breast cancer.
3. Has a history of any severe and/or uncontrolled medical conditions or other conditions that, in the opinion of the investigator, could affect the participant's involvement in the study.
4. Has uncontrolled hypertension
5. Has significant symptoms from peripheral neuropathy
6. Has an active uncontrolled infection
7. Has a history of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in the drug formulation of zanidatamab or other study interventions.
8. Known active hepatitis B or C infection.
9. Has another malignancy diagnosed within the last 5 years. Exceptions include previously treated non melanomatous skin cancers, carcinoma in-situ, and melanoma in-situ.
10. Was treated with chemotherapy, anti-HER2 therapy, radiation therapy, endocrine therapy, or experimental therapy for invasive breast cancer
11. Is planning to receive concurrent therapy with any other investigational agent or anti-cancer therapy not specified in the protocol
12. Receipt of a live vaccine within 4 weeks prior to enrollment
13. Has a known hypersensitivity to any components of the study interventions, including chemotherapy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

125 participants in 3 patient groups

Zanidatamab with paclitaxel

Active Comparator group

Description:

Zanidatamab in combination with chemotherapy paclitaxel

Treatment:

Drug: Paclitaxel

Drug: Zanidatamab

Zanidatamab with docetaxel and carboplatin

Active Comparator group

Description:

Zanidatamab in combination with chemotherapy docetaxel and carboplatin

Treatment:

Drug: Docetaxel

Drug: Carboplatin

Drug: Zanidatamab

Trastuzumab and pertuzumab with docetaxel and carboplatin

Active Comparator group

Description:

Trastuzumab and pertuzumab in combination with chemotherapy docetaxel and carboplatin

Treatment:

Drug: Trastuzumab

Drug: Pertuzumab

Drug: Docetaxel

Drug: Carboplatin